Efficacy verification and microscopic observations of an anticancer peptide, CB1a, on single lung cancer cell

In this work, we introduce a new customized anti-lung cancer peptide, CB1a, with IC₅₀ of about 25.0 ± 1.6 μM on NCI-H460 lung cancer cells. Using a multi-cellular tumor spheroid (MCTS) model, results show that CB1a is potent in preventing the growth of lung cancer tumor-like growths in vitro. Additionally, atomic force microscopy (AFM) was used to examine cell surface damage of a single cancer. The mechanism for cell death under CB1a toxicity was verified as being largely due to cell surface damage. Moreover, with a treatment dosage of CB1a at 25 μM, Young's module (E) shows that the elasticity and stiffness of cancer cell decreased with time such that the interaction time for a 50% reduction of E (IT₅₀) was about 7.0min. This new single-cell toxicity investigation using IT₅₀ under AFM assay can be used to separately verify drug efficacy in support of the traditional IC₅₀ measurement in bulk solution. These results could be of special interest to researchers engaged in new drug development.